News

  The ”FAiTh- Fight Against Thalassemia” patients & parents Association just published their 1st year activity report, after being officially registered as a trust! Read the activities report here:

  Victoria Gray, 34-year-old mother-of-four, has volunteered to be the first American to have their genes edited with the controversial CRISPR technology to treat her SickleCell disease (SCD). For the first time, doctors in the U.S. have used the powerful gene-editing technique CRISPR to try to treat a patient with a ...

World Hepatitis Day (WHD) takes places every year on 28 July bringing the world together under a single theme to raise awareness of the global burden of viral hepatitis and to influence real change. According to the World Health Organization (WHO), Viral hepatitis B and C affect 325 million people ...

Novartis announced earlier today the FDA accepted the company’s Biologics License Application (BLA) and has granted Priority Review for its investigational Sickle Cell (SCD) medicine Crizanlizumab. If FDA-approved, crizanlizumab is expected to represent the first monoclonal antibody targeting the P-selectin mediated multi-cellular adhesion in sickle cell disease! Novartis submitted the application ...

Cell and gene therapies could be literally flying high soon from now! The Italy-based biotech company Anemocyte, in collaboration with RPS Aerospace,  developed a remotely piloted drone system to securely transport final cell and gene therapy products straight from manufacturing sites to clinical centers. The current prototype can also transport ...

From 14 July to 20 August 2019, two nurses from the Nepal Thalassaemia Society Blood Transfusion Centre will have the unique opportunity to receive intensive, official thalassaemia training at the Haematology Department at University College London Hospitals NHS Foundation Trust (UCLH). Nurses and other medical staff often lack knowledge for ...

  The Mumbai Hematology Group, in collaboration with the Youth Thalassemic Alliance, is organizing the 8th Thalassemia Lunch-on Symposium on Saturday, 12th October 2019.  The event will take place in the S P Jain Auditorium of the Bombay Hospital, Mumbai. Several renowned speakers, including Dr Maria-Domenica Cappellini from Italy, will ...

  Bluebird bio Inc. set a price for its gene therapy, Zynteglo, at 1.58 million euros ($1.78 million) over five years, after winning conditional approval in Europe earlier this month to to treat patients 12 years and older with transfusion-dependent β-thalassaemia (TDT), who have no matching donor for a stem ...

  Zynteglo, Bluebird Bio’s ex vivo gene therapy for β-thalassaemia, got a green light from the EMA for conditional marketing authorization making it the 1st gene therapy for patients with thalassaemia to win such an approval.  The one-time gene therapy has been approved for patients 12 years and older with ...